Wegovy Dosage in 2026: The FDA Label Schedule
Wegovy (semaglutide) is a once-weekly injection, and a daily tablet, approved for weight reduction, cardiovascular risk reduction and MASH. The injection label starts at 250 mcg weekly and steps up every 4 weeks through 500, 1,000 (1 mg) and 1,700 mcg (1.7 mg) to a 2,400 mcg (2.4 mg) maintenance dose, with up to 7,200 mcg (7.2 mg) permitted for weight.
Topic: Reading Wegovy’s FDA prescribing information
Audience: Anyone comparing a dosing schedule against its source
Reading time: 9–11 minutes
Not affiliated with Novo Nordisk. Prof. Peptide is not affiliated with, endorsed by, or sponsored by Novo Nordisk. Wegovy is a registered trademark of Novo Nordisk A/S. This page reports what Novo Nordisk’s own prescribing information and FDA’s own publications state; it does not sell, ship, or recommend the branded product.
What Wegovy is
Wegovy is a brand name. Its active ingredient is semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist manufactured by Novo Nordisk. The label states Wegovy injection is indicated, in combination with a reduced-calorie diet and increased physical activity, to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight; to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 12 and older with obesity, or in adults with overweight and at least one weight-related comorbid condition; and, under accelerated approval, for noncirrhotic MASH (metabolic dysfunction-associated steatohepatitis) with moderate to advanced liver fibrosis in adults. The same label also covers a separate oral tablet formulation, indicated for cardiovascular risk reduction and weight reduction in adults — the label’s own revision history shows both its Indications and Usage and Dosage and Administration sections were revised in December 2025, consistent with trade-press reports of a December 22, 2025 approval for the tablet. The tablet is dosed differently from the injection; both schedules are read below.
Semaglutide is also sold under other brand names, at different doses, for different indications — Ozempic (type 2 diabetes) and Rybelsus (an oral form, type 2 diabetes only) are the same molecule with different labels. The Prof. Peptide semaglutide profile covers how the three relate, the mechanism, and the published trial evidence across all of them. This page reads Wegovy’s own label specifically, since its dosing schedule, indications, and cited trials are not identical to Ozempic’s or Rybelsus’s.
What the label specifies
Both schedules below come from the same document — Novo Nordisk, WEGOVY (semaglutide) injection and tablets prescribing information, DailyMed setid ee06186f-2aa3-4990-a760-757579d8f77b, effective June 18, 2026.
Wegovy injection
The table below is Wegovy injection’s recommended dosage, given once weekly by subcutaneous injection, as stated in sections 2.1 and 2.2 of the label.
| Step | Dosage | As specified by the label |
|---|---|---|
| Initiation | 250 mcg once weekly | Weeks 1–4, for all approved indications. |
| First increase | 500 mcg once weekly | Weeks 5–8. |
| Second increase | 1,000 mcg (1 mg) once weekly | Weeks 9–12. |
| Third increase | 1,700 mcg (1.7 mg) once weekly | Weeks 13–16. |
| Maintenance — cardiovascular risk reduction | 2,400 mcg (2.4 mg) (recommended) or 1,700 mcg (1.7 mg) once weekly | Week 17 onward; the label states to consider treatment response and tolerability when selecting between the two. |
| Maintenance — weight reduction | 1,700 mcg (1.7 mg) or 2,400 mcg (2.4 mg) (recommended) once weekly | Week 17 onward; if 2,400 mcg (2.4 mg) is tolerated for ≥4 weeks and additional weight reduction is clinically indicated, the label permits escalation to a maximum of 7,200 mcg (7.2 mg) once weekly. |
Under section 2.4, a missed dose of Wegovy injection is administered as soon as possible if the next scheduled dose is more than 2 days away; if it is less than 2 days away, the missed dose is skipped and the regular schedule resumes. If 2 or more consecutive doses are missed, dosage escalation is reinitiated at a lower dosage. This window is shorter than Ozempic’s label, which allows 5 days before a missed dose is skipped.
Dosage forms and strengths (section 3) list single-dose pens and prefilled syringes at 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg per injection — the label’s strengths are per-injection figures from a prefilled pen, so the label states no reconstitution math. The peptide dosage calculator works out how much bacteriostatic water to add to a research-grade vial and how many syringe units a given amount takes. It does not set a dose.
Wegovy tablets (oral)
The table below is Wegovy tablets’ recommended dosage as stated in section 2.3 of the label, for cardiovascular risk reduction or weight reduction in adults.
| Step | Dosage | As specified by the label |
|---|---|---|
| Starting dosage | 1,500 mcg (1.5 mg) once daily | Days 1–30. |
| First increase | 4,000 mcg (4 mg) once daily | Days 31–60. |
| Second increase | 9,000 mcg (9 mg) once daily | Days 61–90. |
| Maintenance | 25,000 mcg (25 mg) once daily | Day 91 onward, for cardiovascular risk reduction and weight reduction in adults. |
The label states that Wegovy tablets are administered orally once daily on an empty stomach in the morning with up to 4 ounces of plain water only, swallowed whole (not split, crushed, chewed, or dissolved), at least 30 minutes before any food, other beverage, or other oral medication. If the 25,000 mcg (25 mg) maintenance dosage is not tolerated, the label states that switching to Wegovy 1.7 mg injection can be considered.
Section 2.4 states a different missed-dose rule for the tablet than for the injection: a missed dose of Wegovy tablets is skipped and the next dose is taken the following day — there is no days-away calculation, unlike the injection’s 2-day rule above.
Section 2.5 (Switching Between Wegovy Injection and Wegovy Tablets) states that patients taking Wegovy 2.4 mg injection may switch to Wegovy 25 mg tablets one week after discontinuing the injection, initiating the tablet directly at the 25 mg maintenance dosage without repeating the escalation. Patients switching the other direction, from Wegovy 25 mg tablets to injection, initiate Wegovy 2.4 mg subcutaneous injection the day after discontinuing the tablet, again without repeating the injection’s own escalation.
Dosage forms and strengths (section 3) list tablets at 1.5 mg, 4 mg, 9 mg, and 25 mg — distinct strengths from the injection’s per-pen figures above, and not interchangeable milligram-for-milligram given the tablet’s low oral bioavailability. The absorption figures behind that, for every semaglutide tablet, are set out in semaglutide pills vs injection.
How do clinics prescribe Wegovy?
Clinics that publish a Wegovy schedule follow the label’s ladder rather than a schedule of their own: 250 mcg once weekly, stepping up about every four weeks to the 2,400 mcg (2.4 mg) maintenance dose, which takes around 16 weeks. One clinic publishes these steps as its own titration table, from 250 mcg in weeks 1–4 to 2,400 mcg (2.4 mg) from week 17, and leads with the caveat that the schedule that matters is the one the prescriber writes. Another describes the increase as gradual over 16 to 20 weeks, to reduce gastrointestinal side effects. For the tablet, clinics list the label’s four strengths, 1.5, 4, 9 and 25 mg.
The clinic schedules for compounded semaglutide, which sit at or below this ladder, are on the semaglutide dosing guide and the semaglutide profile; the side effects clinics report are with the label’s warnings below.
What the trials administered
Section 14 of the label (Clinical Studies) names Wegovy’s trials as “Study 1” through “Study 10,” each with its own NCT registry number — the label never uses the word “STEP”. “STEP” is the separately published, publicly known name for the weight-reduction trial program; it is noted once below, and the citation follows the label’s own naming. The three trials below are the ones underlying the dosing and outcomes discussed on this page — two for the injection, and Study 7 for the tablet. Each is graded against Prof. Peptide’s standing citation convention — a claim is attributed when a marker resolves to a named, checkable primary source. All three grade as attributed: each is named in the label itself, with a registry number checkable against ClinicalTrials.gov independent of the label.
Study 1 (NCT03574597) — publicly known as SELECT
Multi-national, multi-center, placebo-controlled, double-blind cardiovascular outcomes trial
Arms: Placebo (N=8,801), WEGOVY 2,400 mcg (2.4 mg) injection (N=8,803) — adults 45 years or older with established cardiovascular disease and either obesity or overweight, no history of diabetes
Endpoint reported: Hazard ratio for time to first occurrence of MACE (cardiovascular death, non-fatal MI, or non-fatal stroke): 0.80 (95% CI: 0.72, 0.90), p<0.001. Median follow-up 41.8 months.
Attributed — named and described in full in the label's own Clinical Studies section (14.1), primary source open below.
Study 2 (NCT03548935) — one of the STEP program's trials
68-week, randomized, double-blind, placebo-controlled trial
Arms: Placebo (N=655), WEGOVY 2,400 mcg (2.4 mg) injection (N=1,306) — adults with obesity or overweight and at least one weight-related comorbidity
Endpoint reported: Body weight change from baseline at week 68, per the prescribing label (section 14.2): −2.4% (placebo) vs. −14.9% (WEGOVY 2.4 mg).
Attributed — named and described in full in the label's own Clinical Studies section (14.2), with a registry number checkable against ClinicalTrials.gov independent of the label.
Study 7 (NCT05564117) — WEGOVY 25 mg tablets
64-week, randomized, double-blind, placebo-controlled trial, plus a 7-week off-drug follow-up period
Arms: Placebo (N=102), WEGOVY 25 mg tablets (N=205) — adults with obesity (BMI ≥30 kg/m²) or overweight (BMI 27–29.9 kg/m²) and at least one weight-related comorbidity; patients with type 2 diabetes were excluded. Tablet dosage was escalated to 25,000 mcg (25 mg) over a 12-week period, then held for a 52-week maintenance period.
Endpoint reported: Body weight change from baseline at week 64, per the prescribing label (section 14.2, least-squares means with missing data imputed): −2.4% (placebo) vs. −13.6% (WEGOVY 25 mg tablets); 76.3% of tablet-treated patients achieved ≥5% weight loss, versus 31.3% on placebo. The trial's own paper (OASIS 4, NEJM 2025) reports −2.2% for placebo under its estimate, an 11.4-point difference against the label's 11.2.
Attributed — named and described in full in the label's own Clinical Studies section (14.2), with a registry number (NCT05564117) checkable against ClinicalTrials.gov independent of the label. This is the tablet's own dedicated trial, distinct from the injection trials above.
Ozempic’s label cites a different trial program (the monotherapy trial, SUSTAIN 6, and FLOW) at different doses and different indications. Those figures belong to Ozempic’s own label, not Wegovy’s, even though both products share the same active ingredient — the semaglutide profile covers the trial evidence across brands directly.
The label’s warnings and adverse events
Boxed warning: risk of thyroid C-cell tumors
The label states: “It is unknown whether WEGOVY causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans”; the human relevance of the tumor finding behind the warning has not been determined.
The label states Wegovy is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and instructs counseling patients on the potential risk and on symptoms such as a mass in the neck, dysphagia, dyspnea, or persistent hoarseness.
Table 3 of the label reports adverse reaction rates (≥2% and greater than placebo) among adults treated with the 2,400 mcg (2.4 mg) maintenance dosage for weight reduction:
| Adverse reaction | Placebo (N=1,261) | Wegovy 2,400 mcg (2.4 mg) (N=2,116) |
|---|---|---|
| Nausea | 16% | 44% |
| Diarrhea | 16% | 30% |
| Vomiting | 6% | 24% |
| Constipation | 11% | 24% |
| Abdominal pain | 10% | 20% |
| Headache | 10% | 14% |
| Fatigue | 5% | 11% |
| Dyspepsia | 3% | 9% |
For Wegovy tablets, the label states that adverse-reaction types and frequencies in Study 7 were similar to those in the injection table above, rather than reporting a separate per-reaction breakdown. It does report tablet-specific discontinuation figures: 6.9% of Study 7 participants treated with Wegovy 25 mg tablets permanently discontinued treatment due to adverse reactions, versus 5.9% on placebo; the most common reason was gastrointestinal adverse reactions, reported in 3.4% of tablet-treated participants versus 2% on placebo.
Clinics prescribing semaglutide list nausea, especially during titration, reduced appetite, constipation or diarrhea, and fatigue among the commonly reported side effects; one adds pancreatitis, gallbladder disease and severe gastroparesis as less common but serious. The same clinic monitors HbA1c and fasting glucose, a lipid panel, thyroid function and body composition, and treats a personal or family history of medullary thyroid cancer or MEN 2, pregnancy and a history of pancreatitis as reasons it is generally not appropriate.
Compounding and research-grade semaglutide
Wegovy’s prescribing information does not mention compounding. The word does not appear anywhere in the label. Everything above this section describes a prescription drug product, manufactured by Novo Nordisk and dispensed by a pharmacy against a prescription.
Research-grade semaglutide, of the kind sold by the vendors Prof. Peptide tracks elsewhere on this site, is neither the branded product described above nor a pharmacy-compounded version of it. It is sold labeled for research use, not for human administration, and it is not dispensed against a prescription.
Separately from the branded label, FDA has published its own position on compounded semaglutide. Its April 1, 2026 statement on compounding, once the national GLP-1 supply stabilized, describes the conditions under which a compounded drug can lawfully be exempt under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act, and states FDA’s position that a compounded product is treated as an unlawful copy of a commercially available drug when it shares the same active ingredient, a similar or easily substitutable strength, and the same route of administration — unless a prescriber documents a significant difference for an individual patient.
On April 30, 2026, FDA announced it is proposing to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list entirely, stating it “did not identify a clinical need for outsourcing facilities to compound semaglutide, tirzepatide, and liraglutide from bulk drug substances.” The public comment period on that proposal closed, and FDA has not published a final determination.
FDA also writes that the salt forms some compounders sell, semaglutide sodium and semaglutide acetate, are different active ingredients from those in the approved drugs, and that it is “not aware of any lawful basis for their use in compounding.” It reports adverse events, some requiring hospitalization, linked to dosing errors with compounded injectable semaglutide, and adverse events in patients prescribed compounded semaglutide or tirzepatide “in doses beyond what is in the FDA-approved drug label,” including a faster titration schedule.
None of this changes what the label above states, and none of it describes Prof. Peptide’s vendors as compounding pharmacies — they are not. It is published here because a reader comparing a branded dosing schedule against a research-grade product should be able to see, in one place, that the two are governed by different rules, and that the regulatory status of compounded semaglutide is itself unsettled and separate from both.
How this page differs from Ozempic’s and the semaglutide profile
Wegovy and Ozempic share an active ingredient but not a label. Ozempic’s three indications are glycemic control, cardiovascular risk reduction, and chronic kidney disease risk reduction in adults with type 2 diabetes, capped at 2,000 mcg (2 mg) once weekly, with a 5-day missed-dose window and a single injectable dosage form. Wegovy’s three indications are cardiovascular risk reduction, weight reduction, and noncirrhotic MASH — none of them require type 2 diabetes — escalating to as high as 7,200 mcg (7.2 mg) once weekly for weight reduction, with a shorter 2-day missed-dose window, and a second oral tablet formulation the injectable label doesn’t have. The two labels cite entirely separate trial programs: Ozempic’s monotherapy trial, SUSTAIN 6, and FLOW versus Wegovy’s Study 1, Study 2, and Study 7 above.
The semaglutide profile is a different kind of page: it covers the molecule’s mechanism and the published trial evidence across all semaglutide brands at once, without reading any single FDA label’s escalation schedule, boxed warning, or adverse-event table in the detail this page does: the missed-dose window, the maintenance dosage options and the adverse-reaction percentages at the 2,400 mcg (2.4 mg) dose are figures only Wegovy’s own label states.
FAQ
Is Wegovy the same as semaglutide?
What is the starting dose on the Wegovy label?
Is Wegovy available as a pill?
What is the maximum Wegovy dose?
What happens if a dose is missed?
Does Wegovy carry a boxed warning?
How do clinics prescribe Wegovy?
Is compounded or research-grade semaglutide the same as Wegovy?
References
- Novo Nordisk. WEGOVY (semaglutide) injection and tablets — prescribing information. DailyMed, setid ee06186f-2aa3-4990-a760-757579d8f77b, effective 2026-06-18. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
- U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. Drug Alerts and Statements, 2026-04-01. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
- U.S. Food and Drug Administration. FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List. Press Announcements, 2026-04-30. https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
- U.S. Food and Drug Administration. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Content current as of 2026-10-01; read 2026-11-04. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- Pru. Semaglutide dosage (the titration table). Read November 4 and 6, 2026. https://joinpru.com/blog/semaglutide-dosage
- Clinic sources for the Wegovy schedule and clinic practice, read November 4–6, 2026: Second Nature’s Wegovy page (secondnature.io), Pramah’s semaglutide/Wegovy page (pramahtampa.com), LifeMD’s Wegovy pill page (lifemd.com), and Marek Health’s semaglutide treatment page (marekhealth.com).
- ClinicalTrials.gov. Research Study on Heart Disease in People With Overweight or Obesity (SELECT), NCT03574597. https://clinicaltrials.gov/study/NCT03574597
- ClinicalTrials.gov. Research Study on the Long-term Effects of Semaglutide in Participants With Overweight or Obesity (STEP 1), NCT03548935. https://clinicaltrials.gov/study/NCT03548935
- ClinicalTrials.gov. Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range (Study 7), NCT05564117. https://clinicaltrials.gov/study/NCT05564117
Affiliate disclosure: Prof. Peptide earns a commission on purchases and sign-ups made through its links and codes, at no extra cost to the buyer. Commissions never decide which vendors are listed, how they are ranked or verified, or what Prof. Peptide concludes.
Related pages
- How Is Tirzepatide Dosed? Mounjaro and Zepbound, ComparedTirzepatide has two FDA labels — Mounjaro and Zepbound — with different schedules, maximums, and adverse-event profiles.
- Zepbound Dosage: The FDA Label Schedule and What Clinics ReportZepbound's FDA-approved dosing schedule, the trials behind it, the boxed warning and adverse events from the label, and how research-grade tirzepatide relates to the…
- Guides — Practical Peptide Research ReferencesPractical reference guides for peptide research — injection technique, reconstitution math, syringe sizing, and research fundamentals.
Checked and updated
